Osaka, Japan-based Takeda Pharmaceuticals entered into a strategic collaboration with Teaneck, N.J.-based NuBiyota for its microbial ecosystem therapeutic products. Takeda recently entered into a similar agreement with Finch Therapeutics over its inflammatory bowel disease treatment.
Memphis, Tenn.-based Baptist Memorial Health Care selected Weston, Fla.-based gMed’s gGastro electronic health record system and its gInsignts performance measure platform as its primary procedure report writer. gMEd is a Modernizing Medicine company.
Tel Aviv, Israel-based RedHill Biopharma entered into a licensing agreement with Carcy, N.C.-based Entera Hill for its EnteraGam.
Senior Vice President and General Manager of Bridgewater, N.J.-based Salix Pharmaceuticals Mark McKenna talked to Becker’s ASC Review about his dedication to revolutionizing gastroenterology and preventing GI diseases.
Laval, Canada-based Valeant Pharmaceuticals saw its share price drop 23 percent in March.
After a recent bacterial infection left five patients sick in an overseas facility, Sen. Patty Murray, D-Wash., wrote Tokyo-based Olympus requesting information proving their redesigned duodenoscopes were safe.
More articles on gastroenterology:
Takeda expands gastroenterology efforts: Announces collaboration with NuBiyota: 3 insights
Patient, provider communication poor on how ulcerative colitis impacts quality of life: 4 study insights
GI leader to know: Dr. Seth Gross of NYU Langone Medical Center
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
